检索结果-南通市图书馆

Journal of Wuhan University of Technology(Materials Science) 2024年第4期39卷 912-920页

作者：张超任秀华 BA Dongzhe ZHANG Jianhua li jianyong GUO Mengnan GAO Yinghao WANG Guixin li Jiayang School of Mechanical and Electronic Engineering Shandong Jianzhu UniversityJinan 250101China Key Laboratory of High Efficiency and Clean Mechanical Manufacture Ministry of Education of ChinaSchool of Mechanical EngineeringShandong UniversityJinan 250061China

Because inferior mechanical strength of granite polymer composite(GPC)has become the main drawback limiting its application and popularization,Mo fibers were added into(GPC)to improve its mechanical *** properties of matrix materials with different mass ratio of resin and stabilizer(MRRS)were investigated *** influences of MRRS on interface bonding strength of Mo fiber-matrix,wettability and mechanical strength of GPC were discussed,respectively,and the theoretical calculation result of MRRS k was obtained,with the optimal value of k=*** k=4,tensile strength,tensile strain and fracture stress of the cured resin achieve the maximum *** for k=7,the corresponding values reach the *** the increase of MRRS k,surface free energy of the cured resin first increases and then decreases,while contact angles between Mo sample and matrix have displayed the opposite *** of resin to Mo fiber is the best at k=*** load of Mo fiber and interface bonding strength appear the maximum at k=4,followed by k=5,k=3 the third,and k=7 the *** k=4,mechanical properties of Mo fiber-reinforced GPC are optimal,which is consistent with the result of theoretical *** study is of great significance to get better component formulas of Mo fiber reinforced GPC and to improve its application in machine tools.

关键词： polymer composite fiber mechanical strength interface bonding

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma

在线全文

学校读者我要写书评

暂无评论

Genes & Diseases 2024年第2期11卷 550-553页

作者： Jing Tang Yue li Jiazhu Wu Haorui Shen Hua Yin Jinhua liang li Wang jianyong li Yi Xia Wei Xu Department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjingJiangsu 210029China Key Laboratory of Hematology of Nanjing Medical University NanjingJiangsu 210029China Collaborative Innovation Center for Cancer Personalized Medicine NanjingJiangsu 210029China

PR/SET domain 1(PRDM1)gene is located on chromosome 6q21,encoding the B lymphocyte-induced maturation protein 1(BliMP1).1 It is reported that loss of PRDM1 function is exacerbated in activated B-cell-like(ABC)-diffuse large B cell lymphoma(DLBCL)and associated with inferior ***,it remains unclear what leads to PRDM1 inactivation and the drug resistance mechanism caused by abnormal inactivation of *** investigated the contribution of PRDM1 gene as a prognosis and potential therapeutic target for ABC-DLBCL patients and further clarified the possible mechanism of PRDM1 abnormal *** first proposed that TP53 could regulate PRDM1 by histone ubiquitination modification at the post-transcriptional level.

关键词： PRDM1 TP53 therapeutic

Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Genes & Diseases 2024年第4期11卷 116-119页

作者： Yi Xia li Wang Jinhua liang Haorui Shen Jiazhu Wu Hua Yin Yue li Huayuan Zhu jianyong li Wei Xu Department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjingJiangsu 210029China Key Laboratory of Hematology of Nanjing Medical University NanjingJiangsu 210029China Collaborative Innovation Center for Cancer Personalized Medicine NanjingJiangsu 210029China

Diffuse large B-cell lymphoma(DLBCL)is the most common lymphoma with heterogeneous clinical *** who are primarily refractory to the frontline therapy or relapse less than 12 months after diagnosis have an extremely di... 详细信息

关键词： lymphoma diagnosis clinical

Chidamide plus prednisone,cyclophosphamide,and thalidomide for relapsed or refractory peripheral T-cell lymphoma:A multicenter phase II trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第13期137卷 1576-1582页

作者： Jinhua liang li Wang Xiaodong Wang Guohui Cui Jianfeng Zhou Tongyao Xing Kaixin Du Jingyan Xu Luqun Wang Rong liang Biyun Chen Jian Cheng Haorui Shen jianyong li Wei Xu Department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjingJiangsu 210029China Key Laboratory of Hematology of Nanjing Medical University NanjingJiangsu 210029China Collaborative Innovation Center for Cancer Personalized Medicine NanjingJiangsu 210029China Department of Hematology Sichuan Academy of Medical Sciences&Sichuan Provincial People’s HospitalSchool of Medicine of University of Electronic Science and Technology of ChinaChengduSichuan 610000China Department of Hematology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430022China Department of Hematology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China Department of Hematology Nanjing Drum Tower HospitalNanjing University Medical SchoolNanjingJiangsu 210008China Department of Hematology Qilu Hospital of Shandong UniversityJinanShandong 250000China Department of Hematology Xijing HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710032China Department of Hematology Fujian Provincial HospitalFuzhouFujian 350001China Department of Hematology Zhongda HospitalMedical School of Southeast UniversityNanjingJiangsu 210009China

Background:Although the treatment of peripheral T-cell lymphoma(PTCL)has undergone advancements during the past several years,the response rate and long-term effects with respect to patients with PTCL remain unsatisfactory—particularly for relapsed or refractory(R/R)*** phase II trial was designed to explore the efficacy and safety of an all-oral regimen of chidamide plus prednisone,cyclophosphamide,and thalidomide(CPCT)for R/R PTCL patients who could not tolerate the standard chemotherapy for a variety of ***:We conducted a multicenter phase II clinical trial in which we combined chidamide(30 mg twice weekly)with prednisone(20 mg daily after breakfast),cyclophosphamide(50 mg daily after lunch),and thalidomide(100 mg daily at bedtime)(the CPCT regimen)for a total of fewer than 12 cycles as an induction-combined treatment period,and then applied chidamide as single-drug ***-five patients were ultimately enrolled from August 2016 to April 2021 with respect to Chinese patients at nine *** primary objective was to assess the overall response rate(ORR)after the treatment with ***:Of the 45 enrolled patients,the optimal ORR and complete response(CR)/CR unconfirmed(CRu)were 71.1%(32/45)and 28.9%(13/45),respectively,and after a median follow-up period of 56 months,the median progression-free survival(PFS)and overall survival(OS)were 8.5 months and 17.2 months,*** five-year PFS and OS rates were 21.2%(95%confidence interval[CI],7.9-34.5%)and 43.8%(95%CI,28.3-59.3%),*** most common adverse event was neutropenia(20/45,44.4%),but we observed no treatment-related ***:The all-oral CPCT regimen was an effective and safe regimen for R/R PTCL patients who could not tolerate standard chemotherapy for various *** Registration:***,NCT02879526.

关键词： Peripheral T-cell lymphoma Chidamide Prednisone Cyclophosphamide Thalidomide All-oral regimen

慢性淋巴细胞白血病中B细胞受体同型模式的生物学特征和临床意义

在线全文

学校读者我要写书评

暂无评论

中华血液学杂志 2024年第2期45卷 197-202页

作者：邱彤璐李建勇夏奕南京医科大学第一附属医院江苏省人民医院血液科南京医科大学血液研究重点实验室江苏省肿瘤个体化医学协同创新中心南京210029

慢性淋巴细胞白血病(CLL)是西方成人最常见的白血病,尽管CLL在亚洲人种中发病率偏低,但随着人口老龄化,CLL发病率在我国呈上升趋势。CLL细胞与微环境的交互中,B细胞受体免疫球蛋白(B-cell receptor immunoglobulin,BCR IG)对抗原的识别... 详细信息

慢性淋巴细胞白血病(CLL)是西方成人最常见的白血病,尽管CLL在亚洲人种中发病率偏低,但随着人口老龄化,CLL发病率在我国呈上升趋势。CLL细胞与微环境的交互中,B细胞受体免疫球蛋白(B-cell receptor immunoglobulin,BCR IG)对抗原的识别起重要作用,免疫球蛋白重链可变区(IG heavy variable region,IGHV)的突变状态更是判断CLL预后的经典标志物。超过40%的CLL患者间存在IGHV的偏向性使用和高度相似的重链可变区互补决定区3(heavy complementarity-determining region 3,HCDR3)氨基酸片段,此现象称为同型模式BCR。不同亚群的同型模式BCR存在独特的生物学和临床特征。其中IGHV有突变但预后差的#2亚群和发生Richter转化风险高的#8亚群被欧洲CLL研究启动组推荐纳入IGHV突变状态的临床报告之中。本文综述CLL中同型模式BCR的定义、分布、生物学特征和临床意义。

关键词：慢性淋巴细胞白血病 B细胞受体互补决定区3 Richter 免疫球蛋白偏向性重链可变区临床报告

TLR7/8激动剂及其在畜禽疾病防治中的潜在应用

在线全文

学校读者我要写书评

暂无评论

中国兽医学报 2024年第1期44卷 206-216页

作者：刘畅李剑勇中国农业科学院兰州畜牧与兽药研究所农业农村部兽用药物创制重点实验室/甘肃省新兽药工程重点实验室甘肃兰州730050

TLR7/8是动物体内重要的模式识别受体(pattern recognition receptors,PRRs),启动固有免疫并激活适应性免疫,在病原感染中发挥重要作用。TLR7/8激动剂具有增强机体免疫应答的作用,能够激活免疫细胞,调节炎性细胞因子的产生,对加速病原... 详细信息

TLR7/8是动物体内重要的模式识别受体(pattern recognition receptors,PRRs),启动固有免疫并激活适应性免疫,在病原感染中发挥重要作用。TLR7/8激动剂具有增强机体免疫应答的作用,能够激活免疫细胞,调节炎性细胞因子的产生,对加速病原清除具有重要意义,被认为是许多疾病的潜在防治药物,有希望用于治疗病毒感染、肿瘤等疾病,或作为免疫佐剂为动物机体提供持久的抗体保护。常见的TLR7/8激动剂包括咪唑喹啉类衍生物和核苷类似物等,有些药物已进入临床研究阶段,但仅有少数获批临床。现主要围绕TLR7/8激动剂及其在抗病毒、免疫佐剂等方面的潜在应用进行综述。

关键词： TLR7/8激动剂免疫增强剂畜禽疾病防治抗病毒免疫佐剂

在线全文

学校读者我要写书评

暂无评论

原发纵隔大B细胞淋巴瘤的治疗进展

中华血液学杂志 2024年第1期45卷 98-102页

作者：陈吕雯李建勇范磊南京医科大学第一附属医院江苏省人民医院血液科南京210029

原发纵隔大B细胞淋巴瘤(PMBCL)是一种起源于胸腺的侵袭性B细胞淋巴瘤。具有不同于非特指型弥漫大B细胞淋巴瘤的临床和生物学特征,PMBCL好发于年轻女性,通常表现为前纵隔巨大肿块,大多数患者就诊时处于Ⅰ~Ⅱ期,目前尚无标准的PMBCL预后... 详细信息

原发纵隔大B细胞淋巴瘤(PMBCL)是一种起源于胸腺的侵袭性B细胞淋巴瘤。具有不同于非特指型弥漫大B细胞淋巴瘤的临床和生物学特征,PMBCL好发于年轻女性,通常表现为前纵隔巨大肿块,大多数患者就诊时处于Ⅰ~Ⅱ期,目前尚无标准的PMBCL预后评分系统。PMBCL治疗多采用免疫化疗,但最佳一线治疗方案尚无定论,并且放疗的地位存在争议,PET-CT指导治疗的价值有待进一步证实。复发/难治PMBCL预后较差,PD-1抑制剂、维布妥昔单抗和CAR-T细胞等新型疗法有助于改善此类患者生存。

关键词：弥漫大B细胞淋巴瘤前纵隔免疫化疗原发纵隔大B细胞淋巴瘤一线治疗方案年轻女性复发/难治指导治疗

在线全文

学校读者我要写书评

暂无评论

凹凸棒石的改性方式及其在动物生产中的应用

中国饲料 2024年第11期 1-7页

作者：马丹倩李剑勇中国农业科学院兰州畜牧与兽药研究所农业农村部兽用药物创制重点实验室甘肃省新兽药工程重点实验室甘肃兰州730050

凹凸棒石(APT)是具有强吸附能力和离子交换能力的含水富镁铝硅酸盐黏土,进入动物肠道后能覆盖在肠道黏膜表面,保护肠道黏膜,减少与致病菌及其毒素的接触,能够提高动物机体免疫,促进畜禽生长。本文就凹凸棒石晶体结构、理化性质、改性方... 详细信息

凹凸棒石(APT)是具有强吸附能力和离子交换能力的含水富镁铝硅酸盐黏土,进入动物肠道后能覆盖在肠道黏膜表面,保护肠道黏膜,减少与致病菌及其毒素的接触,能够提高动物机体免疫,促进畜禽生长。本文就凹凸棒石晶体结构、理化性质、改性方法及凹凸棒石在动物生产中的应用等进行综述,为凹凸棒石的开发和在动物生产中的应用提供参考。

关键词：凹凸棒石改性动物生产

同方期刊数据库

溅射技术与基体偏压对TiB_(x)涂层结构和力学性能的影响

在线全文

学校读者我要写书评

暂无评论

表面技术 2024年第15期53卷 206-215页

作者：谷佳宾李建勇金杰李刘合北京交通大学机械与电子控制工程学院北京100044 北京交通大学载运工具先进制造与测控技术教育部重点实验室北京100044 北京航空航天大学机械工程及自动化学院北京100191

目的改善TiB_(x)涂层的残余应力,提高其力学性能。方法采用不同的磁控溅射技术(dcMS、HiPMS、Hybrid)和基体偏压制备TiB_(x)涂层。通过电子探针显微分析仪(EPMA)测试TiB_(x)涂层的化学成分,采用扫描电子显微镜(SEM)和X射线衍射仪(XRD)... 详细信息

目的改善TiB_(x)涂层的残余应力,提高其力学性能。方法采用不同的磁控溅射技术(dcMS、HiPMS、Hybrid)和基体偏压制备TiB_(x)涂层。通过电子探针显微分析仪(EPMA)测试TiB_(x)涂层的化学成分,采用扫描电子显微镜(SEM)和X射线衍射仪(XRD)表征涂层的表面形貌、组织结构特征、相组成和择优取向,通过sin^(2)ψ法、纳米压痕仪和洛氏压痕法分别测试TiB_(x)涂层的残余应力、纳米硬度和膜层/基体结合强度。结果溅射技术和基体偏压对TiB_(x)涂层的组织结构和力学性能都有着显著的影响。在基体旋转条件下,不同溅射技术和基体偏压制备的涂层均呈现出TiB_(2)-(001)择优取向。随基体偏压的升高,涂层的残余应力呈现出先增大、后减小的规律。偏压相同时,HiPIMS技术制备的TiB_(x)涂层具有最高的残余应力。随着基体偏压的增加,TiB_(x)涂层的纳米硬度和弹性模量不断增加,在偏压为–130 V时,Hybrid-TiB_(x)涂层具有最高的纳米硬度(40.1GPa)。偏压相同时,dcMS-TiB_(x)和Hybrid-TiB_(x)涂层表现出优异的膜层/基体结合强度(HF1-HF2级),而HiPIMS涂层表现出较差的膜层/基体结合强度(HF1-HF4级)。结论溅射技术和基体偏压对TiB_(x)涂层的微观组织结构和力学性能有着重要的影响,Hybrid模式结合了dcMS模式和HiPMS模式的优点,Hybrid-TiB_(x)涂层呈现出最优的综合力学性能(高的纳米硬度、沉积速率和膜层/基体结合强度)。

关键词：磁控溅射 TiB_(x)涂层基体偏压 Hybrid 微观组织结构力学性能

质谱流式及相关成像技术在淋巴瘤微环境研究中的应用

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

中华检验医学杂志 2024年第3期47卷 341-348页

作者：陈睿泽顾博涵李建勇夏奕南京医科大学第一附属医院江苏省人民医院血液科南京医科大学血液研究重点实验室江苏省肿瘤个体化医学协同创新中心南京210029 苏州大学医学院苏州215031

肿瘤微环境(TME)由肿瘤细胞、免疫细胞和基质细胞共同构成, 每个细胞组分之间的相互作用对肿瘤发生发展起着关键影响。TME中免疫细胞和基质细胞通过引起细胞毒性或炎症反应来对抗肿瘤细胞, 但它们也通过一系列免疫调节机制参与肿瘤逃逸... 详细信息

肿瘤微环境(TME)由肿瘤细胞、免疫细胞和基质细胞共同构成, 每个细胞组分之间的相互作用对肿瘤发生发展起着关键影响。TME中免疫细胞和基质细胞通过引起细胞毒性或炎症反应来对抗肿瘤细胞, 但它们也通过一系列免疫调节机制参与肿瘤逃逸。既往抗淋巴瘤的治疗主要靶向恶性细胞本身, 但随着免疫检查点抑制剂、双特异性抗体和嵌合抗原受体T细胞等免疫治疗的临床应用, 消除TME对肿瘤细胞的保护作用也越发得到重视。借助质谱流式分析仪(CyTOF)和成像质谱流式细胞术(IMC)高通量和高维数据的解析能力, 大样本量解析淋巴瘤TME构成已经成为可能。

关键词：淋巴瘤微环境质谱流式